RxDoctor Payments Data

Warren Brandle, MD

Family Medicine · Gold River, CANPI 1790745263

Payments from drug & device makers

$28,453in general payments, 2019–2025

Across 97 payments — averaging $293.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$27K
  • Seqirus USA Inc$893
  • Boehringer Ingelheim$343
  • Novo Nordisk$196
  • Lilly USA, LLC$106
  • Merck$56
  • plus $156 from 7 others

What the payments were for

  • Consulting fees$7123%
  • Speaking & faculty fees$21,98077%
  • Travel & lodging$3,53412%
  • Food & beverage$2,2278%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,453 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$269,411
Medicare patients
305
Services billed
2,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$61,927
EliquisApixaban35$43,149
OzempicSemaglutide14$16,927
EntrestoSacubitril/Valsartan14$13,270
XareltoRivaroxaban13$12,532
Potassium Chloride52$4,686
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,942
Rosuvastatin Calcium146$3,560
Levothyroxine Sodium220$3,293
Telmisartan72$2,934
Celecoxib54$2,796
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen112$2,159
Clonidine13$2,033
Metoprolol Succinate108$1,961
Testosterone12$1,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$343$61,92743 claims
PfizerEliquis$11$43,14935 claims
Novo NordiskOzempic$196$16,92714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Gold River

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →